Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 17Carcinoma, Hepatocellular 5Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Liver Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Stomach Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1

Interventions

durvalumab 13Bevacizumab 11Nivolumab 10tremelimumab 7pembrolizumab 6lenvatinib 6fludarabine 6Cyclophosphamide 6atezolizumab 4Radiosurgery 4Cisplatin 4toripalimab 3relatlimab 3Magnetic Resonance Imaging 3Ipilimumab 3Gemcitabine 3X-Rays 2Standard of Care 2Sorafenib 2Riluzole 2Radiotherapy 2Photons 2Patient Navigation 2Lidocaine 2Hepatectomy 2Dexamethasone 2Biopsy 2trastuzumab deruxtecan 1tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × relatlimab × 1 year × Clear all
NCT05337137 2026-01-12

RELATIVITY-106

Bristol-Myers Squibb

Phase 1/2 Completed
83 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04567615 2026-01-08

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Bristol-Myers Squibb

Phase 2 Completed
266 enrolled 28 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡